Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Sa | Virogates A-S zeigt Umsatzwachstum trotz anhaltender Verluste | 1 | IT BOLTWISE | ||
20.03. | ViroGates A/S: ViroGates announces its Annual Report 2024 | 23 | GlobeNewswire (Europe) | Company Announcement no. 3/2025 (March 20, 2025)
Revenue declines by 12 % compared to last year as ViroGates continues the transition into the health- and longevity segment and fosters strategic partnerships
BIRKERØD... ► Artikel lesen | |
VIROGATES Aktie jetzt für 0€ handeln | |||||
07.11.24 | ViroGates A/S: ViroGates announces its Interim Report for Q1-Q3 2024: Revenues are disappointing, but strategic refocusing will pave the way for future growth | 162 | GlobeNewswire (Europe) | Company Announcement no. 9/2024 (November 07, 2024)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for the measurement of chronic... ► Artikel lesen | |
06.11.24 | First North Denmark: ViroGates A/S - increase | 294 | GlobeNewswire | New shares in ViroGates A/S will be admitted to trading on Nasdaq First North
Growth Market Denmark as per 8 November 2024. New shares are issued due to a
directed issue of new shares.
Name: ... ► Artikel lesen | |
21.10.24 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 21.10.2024 | 521 | Xetra Newsboard | The following instruments on XETRA do have their first trading 21.10.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 21.10.2024
Aktien
1 AU000000ARB5 ARB Corporation Ltd.
2... ► Artikel lesen | |
14.10.24 | ViroGates A/S: ViroGates announces a distribution agreement with suPAR Health and a directed issue of shares to suPAR Remedy LLC | 215 | GlobeNewswire (Europe) | Company Announcement no. 8/2024 (October 14, 2024)
ViroGates announces an agreement with US-based suPAR Health to distribute its blood test for chronic inflammation within the United States. ViroGates... ► Artikel lesen | |
15.08.24 | ViroGates A/S: ViroGates announces its half-year report for H1 2024: Revenue for the first half-year of 2024 falls behind the same period in 2023 due to lower activity among research customers | 96 | GlobeNewswire (Europe) | Company Announcement no. 7/2024 (August 15, 2024)
Inside informationBIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for better... ► Artikel lesen | |
17.07.24 | ViroGates A/S: ViroGates announces revised financial guidance for 2024 | 167 | GlobeNewswire (Europe) | Company Announcement no. 6/2024 (July 17, 2024)
Inside informationBIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for better triaging... ► Artikel lesen | |
02.05.24 | ViroGates A/S: ViroGates announces its Interim Report for Q1, 2024: Quarterly revenue up 14% compared to Q1, 2023 | 124 | GlobeNewswire (Europe) | 2.5.2024 11:20:15 CEST | ViroGates |
Interim information
COMPANY ANNOUNCEMENT - No. 5-2024 - 02 May 2024- Inside information
BIRKERØD, DENMARK - ViroGates A/S announces its Interim Report for the... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
TEMPUS AI | 52,65 | 0,00 % | Why Tempus AI Inc. (TEM) Crashed On Wednesday? | ||
23ANDME | 0,795 | 0,00 % | 23andMe: Genialer Short-Trade beschert Anlegerkreis +60% Profit | Auch diese Woche hat es in den Community-Depots gekracht - im besten Sinne: Ein Short-Tipp gegen 23andMe brachte sharedealsPlus-Mitgliedern +60% Rendite! Mit wenigen Minuten Aufwand kannst auch Du in... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,090 | 0,00 % | Why Recursion Pharmaceuticals Inc. (RXRX) Performed Worst On Tuesday? | ||
DERMATA THERAPEUTICS | 1,380 | 0,00 % | Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules | SAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of... ► Artikel lesen | |
EVOTEC | 5,945 | -2,14 % | Evotec, NetraMark, Novo Nordisk - vom Labor zur goldenen digitalen Zukunft mit Künstlicher Intelligenz | Die Pharmabranche erlebt eine Revolution, die alles verändert! Künstliche Intelligenz jagt durch die Labore und schneidet alte Zöpfe ab. Algorithmen durchforsten Milliarden chemischer Strukturen in... ► Artikel lesen | |
NKARTA | 1,965 | 0,00 % | Nkarta, Inc.: Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights | Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimmune... ► Artikel lesen | |
89BIO | 9,095 | 0,00 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,690 | 0,00 % | Summit Therapeutics Aktie: Wachstum lässt staunen! | Innovativer PD-1/VEGF-Antikörper Ivonescimab wird mit Pfizers ADCs kombiniert, während das Unternehmen trotz finanzieller Herausforderungen Talent akquiriert. Summit Therapeutics hat eine bedeutende... ► Artikel lesen | |
QIAGEN | 36,875 | +0,10 % | Biotech Report: Sektor unter Druck - Evotec verlieren, Qiagen behauptet | (shareribs.com) Frankfurt / New York 26.03.2025 - Biotechwerte tendierten im deutschen Handel schwächer, lediglich 4SC konnte leichte Kursgewinne verbuchen. An der Wall Street rutschte der Sektor ab.... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 50,86 | 0,00 % | Dianne C. Whitfield Sells 2,137 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock | ||
CUREVAC | 2,990 | +3,10 % | CureVac Aktie: Bemerkenswerter Aufschwung! | Der Tübinger Impfstoffhersteller meldet beeindruckendes Quartalsergebnis mit 542,57 Millionen USD Umsatz, während die Aktie zwischen 2,06 und 4,98 EUR schwankt. Die CureVac-Aktie zeigte am Donnerstag... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 23,310 | 0,00 % | Truist maintains Buy rating on Edgewise Therapeutics stock | ||
AVIDITY BIOSCIENCES | 32,340 | +0,90 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
SPRINGWORKS THERAPEUTICS | 47,730 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
BB BIOTECH | 33,150 | -0,75 % | Dividendenbekanntmachungen (21.03.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AECON GROUP INC CA00762V1094 0,19 CAD 0,1221 EUR ALBANY INTERNATIONAL CORP US0123481089 0,27 USD 0,2486 EUR ALGOMA STEEL GROUP... ► Artikel lesen |